Australian cell therapy company Cynata Therapeutics (ASX:CYP) has announced that St George Hospital in Sydney is now a participating site and is seeking to recruit patients in the MEND clinical trial.
The pilot, open-label, randomised controlled clinical trial is investigating the early efficacy of CYP-001 in adults admitted to intensive care with respiratory failure.
Cynata’s chief medical officer Dr Jolanta Airey said,& “We are very pleased St George Hospital is now participating in the MEND trial. We passed the halfway point in the trial several months ago but we are also taking additional steps to further increase the pool of potential subjects despite continued challenges faced by the hospital system.
“We expect that the addition of this large teaching hospital will accelerate active participation of trial subjects and provide greater assurance toward timely completion later this year.”
The St George Hospital and Health Services is part of the South Eastern Sydney Local Health District. It is an accredited, principal teaching hospital of the University of New South Wales and, with around 550 beds, is the largest hospital within the Local Health District and among the leading centres for trauma and emergency management in the State.
The MEND trial aims to recruit 24 adult patients admitted to intensive care with respiratory failure who will be randomly assigned to receive standard care or Cynata’s Cymerus mesenchymal stem cell product CYP-001 plus standard care.
